50
Participants
Start Date
February 23, 2018
Primary Completion Date
April 1, 2023
Study Completion Date
December 1, 2027
Ibrutinib
Ibrutinib will be stopped at inclusion in the and the patient will be followed OFF therapy. At clinical progress, ibrutinib will be restarted (ON period) at the same standard dose as used at inclusion. When the patient achieve at least partial response again, a new OFF period is started, and so on.
RECRUITING
St Olavs Hospital, Trondheim
RECRUITING
Karolinska University Hospital, Stockholm
RECRUITING
Falu lasarett, Falun
RECRUITING
Gävle Hospital, Gävle
NOT_YET_RECRUITING
Skåne University Hospital, Lund
NOT_YET_RECRUITING
Sahlgrenska University Hospital, Gothenburg
RECRUITING
Örebro University Hospital, Örebro
NOT_YET_RECRUITING
Norrland's University Hospital, Umeå
RECRUITING
Akademiska hospital, Uppsala
Jeanette Lundin
OTHER